SPP1, a potential therapeutic target and biomarker for lung cancer: functional insights through computational studies

Abstract

NIH reported 128 different types of cancer of which lung cancer is the leading cause of mortality. Globally, it is estimated that on average one in every seventeen hospitalized patients was deceased. There are plenty of studies that have been reported on lung cancer draggability and therapeutics, but yet a protein that plays a central specific to cure the disease remains unclear. So, this study is designed to identify the possible therapeutic targets and biomarkers that can be used for the potential treatment of lung cancers. In order to identify differentially expressed genes, 39 microarray datasets of lung cancer patients were obtained from various demographic regions of the GEO database available at NCBI. After annotating statistically, 6229 up-regulated genes and 10324 down-regulated genes were found. Out of 17 up-regulated genes and significant genes, we selected SPP1 (osteopontin) through virtual screening studies. We found functional interactions with the other cancer-associated genes such as VEGF, FGA, JUN, EGFR, and TGFB1. For the virtual screening studies,198 biological compounds were retrieved from the ACNPD database and docked with SPP1 protein (PDBID: 3DSF). In the results, two highly potential compounds secoisolariciresinol diglucoside (-12.9 kcal/mol), and Hesperidin (-12.0 kcal/mol) showed the highest binding affinity. The stability of the complex was accessed by 100 ns simulation in an SPC water model. From the functional insights obtained through these computational studies, we report that SPP1 could be a potential biomarker and successive therapeutic protein target for lung cancer treatment.

Communicated by Ramaswamy H. Sarma

Keywords:

• Lung cancer
• gene expression analysis
• gene network analysis
• molecular docking
• molecular dynamics simulation

Disclosure statement

The authors declare no financial or author conflict.

Ethics statement

The analysis is based on secondary data, and no data have been taken directly from humans or animals. No ethical responsibilities are liable.

Additional information

Funding

For financial support, the authors gratefully acknowledge the RUSA 2.0—BCTRC (Bharathiar Cancer Theranostic Research Center) (No. BU/RUSA 2.0/2021/BCTRC/PA/958-2).